Arcturus Therapeutics Holdings Inc.
Description
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
About
CEO
Mr. Joseph E. Payne M.Sc.
Employees
180
Instrument type
Common Stock
Sector
Healthcare
Industry
Biotechnology
MIC code
XNMS
Address
10628 Science Center Drive, San Diego, CA 92121, United States
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Nov 6, 2025 | — | — | — | — |
| Aug 4, 2025 | — | — | — | — |
| May 6, 2025 | — | — | — | — |
| Mar 6, 2025 | -0.33 | — | — | — |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Next Year
(Dec 2025)
|
|||
|---|---|---|---|---|
| Number of analysts | — | 5 | — | 8 |
| Average estimate | — | -0.23 | — | -1.48 |
| Low estimate | — | -0.69 | — | -5.15 |
| High estimate | — | 0.00 | — | 3.12 |
| Last year EPS | — | -1.00 | — | -2.34 |
[stock_revenue_estimate]
Growth estimates
Current qtr
-40.960%
Next qtr. (Mar 2025)
76.800%
Current year
-944.970%
Next year (Dec 2025)
36.530%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total reported revenue | 157.75M | 205.76M | 12.36M | 9.54M | 20.79M |
| Cost of revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating expense | |||||
| Research & development | 192.13M | 147.75M | 173.76M | 57.85M | 33.64M |
| Selling general and admin | 52.87M | 46.07M | 41.45M | 23.22M | 12.66M |
| Other operating expenses | -9.05M | -244,000 | — | — | — |
| Operating income | -78.21M | 12.18M | -202.85M | -71.52M | -25.51M |
| Non operating interest income | |||||
| Income | 17.36M | 2.58M | 753,000 | 470,000 | 408,000 |
| Expense | 767,000 | 3.00M | 2.67M | 831,000 | 854,000 |
| Other income expense | 33.72M | -1.11M | 1.10M | -263,000 | -32,000 |
| Pretax income | -27.89M | 10.64M | -203.67M | -72.15M | -25.99M |
| Tax provision | 1.84M | 1.30M | — | — | — |
| Net income | -29.73M | 9.35M | -203.67M | -72.15M | -25.99M |
| Basic EPS | -1.00 | 0.35 | -7.74 | -3.55 | -2.15 |
| Diluted EPS | -1.00 | 0.35 | -7.74 | -3.55 | -2.15 |
| Basic average shares | 26.63M | 26.45M | 26.32M | 20.31M | 12.07M |
| Diluted average shares | 26.63M | 26.45M | 26.32M | 20.31M | 12.07M |
| EBITDA | -57.89M | 15.77M | -202.24M | -70.44M | -24.45M |
| Net income from continuing op. | -29.73M | 9.35M | -203.67M | -72.15M | -25.99M |
| Minority interests | — | — | — | — | — |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Fiscal date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 429.40M | 450.39M | 392.81M | 476.46M | 82.14M |
| Current assets | |||||
| Cash | — | — | — | — | — |
| Cash equivalents | — | — | — | — | — |
| Cash and cash equivalents | 292.01M | 391.88M | 370.49M | 462.90M | 71.35M |
| Other short term investments | — | — | — | — | — |
| Accounts receivable | 32.06M | 2.76M | 3.37M | 2.13M | 2.18M |
| Other receivables | — | — | — | — | — |
| Inventory | — | — | — | — | — |
| Prepaid assets | — | — | 5.10M | 2.77M | 758,000 |
| Restricted cash | 55.00M | — | — | — | — |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | 7.52M | 8.69M | 5.10M | 2.77M | 758,000 |
| Non current assets | |||||
| Properties | 44.55M | 42.80M | 12.35M | 10.72M | 8.79M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 2.23M | 2.11M | 1.06M | 858,000 | 832,000 |
| Construction in progress | 233,000 | 3.34M | 2.06M | — | — |
| Leases | 2.66M | 2.49M | 44,000 | 44,000 | 40,000 |
| Accumulated depreciation | -8.74M | -5.78M | -4.26M | -3.06M | -2.18M |
| Goodwill | — | — | — | — | — |
| Investment properties | — | — | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | — | — | — | — | — |
| Investments and advances | — | — | 515,000 | — | 263,000 |
| Other non current assets | 1.89M | 2.09M | 2.08M | 107,000 | 107,000 |
| Total liabilities | 150.89M | 180.08M | 164.60M | 79.90M | 56.35M |
| Current liabilities | |||||
| Accounts payable | 5.28M | 7.45M | 10.06M | 10.77M | 5.79M |
| Accrued expenses | 18.50M | 13.55M | 18.41M | 15.66M | 4.70M |
| Short term debt | 4.31M | 64.54M | 24.01M | 2.88M | 827,000 |
| Deferred revenue | 47.34M | 36.12M | 43.48M | 18.11M | 8.40M |
| Tax payable | 641,000 | 1.30M | — | — | — |
| Pensions | 5.92M | 4.04M | 3.58M | 2.10M | 1.61M |
| Other current liabilities | — | — | — | 1.76M | — |
| Non current liabilities | |||||
| Long term debt | 25.91M | 30.22M | 45.14M | 17.87M | 19.85M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | — | — | — | — | — |
| Derivative product liabilities | — | — | — | — | — |
| Other non current liabilities | 497,000 | 2.80M | — | — | — |
| Shareholders equity | |||||
| Common stock | 27,000 | 27,000 | 26,000 | 26,000 | 15,000 |
| Retained earnings | -367.87M | -338.14M | -347.49M | -143.82M | -71.67M |
| Other shareholders equity | — | — | — | — | — |
| Total shareholders equity | 278.51M | 270.31M | 228.21M | 396.55M | 25.79M |
| Additional paid in capital | 646.35M | 608.43M | 575.68M | 540.34M | 97.45M |
| Treasury stock | — | — | — | — | — |
| Minority interest | — | — | — | — | — |
Cash flow statement
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||
| Net Income | -29.73M | 9.35M | -203.67M | -72.15M | -25.99M | -21.79M | -10.90M | -1.57M | -1.90M | -32.83M | -10.55M | -1.58M | -3.93M |
| Depreciation | 2.96M | 1.53M | 1.19M | 882,000 | 684,000 | 582,000 | 410,000 | 294,000 | 192,000 | 31,000 | 9,000 | 7,000 | 6,000 |
| Deferred Taxes | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | 34.65M | 30.61M | 28.92M | 6.76M | 1.98M | 1.26M | 2.17M | 300,000 | 99,000 | 4.09M | 1.54M | 26,000 | 1.55M |
| Other Non-Cash Items | 502,000 | 2.17M | 6.99M | 162,000 | 873,000 | 38,000 | 498,000 | 545,000 | 251,000 | 4.09M | 203,000 | 62,000 | — |
| Accounts Receivable | -29.30M | 603,000 | -1.24M | 54,000 | 2.30M | -4.00M | 3.15M | -1.56M | -2.08M | -313,000 | -32,000 | 12,000 | -49,000 |
| Accounts Payable | -2.24M | -3.11M | -769,000 | 4.81M | 3.16M | 578,000 | -1.54M | 2.54M | 240,000 | 258,000 | 24,000 | -101,000 | 95,000 |
| Other Assets & Liabilities | 38.34M | -15.91M | 32.84M | 7.04M | 8.97M | 159,000 | 6.05M | -3.40M | 10.99M | -38,000 | -54,000 | 2,000 | — |
| Operating Cash Flow | 15.19M | 25.24M | -135.75M | -52.43M | -8.03M | -23.17M | -154,000 | -2.85M | 7.79M | -24.72M | -8.86M | -1.57M | -2.32M |
| Investing Activities | |||||||||||||
| Capital Expenditures | -2.90M | -7.73M | -3.41M | -1.74M | -818,000 | -1.48M | -222,000 | -688,000 | -220,000 | -79,000 | -39,000 | — | -24,000 |
| Net Intangibles | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Acquisitions | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Purchase of Investments | — | — | — | — | — | -6.59M | — | -17.37M | -33.50M | — | -28.01M | — | -517,000 |
| Sale of Investments | — | — | — | — | — | 30.21M | 10.58M | 22.33M | — | 8.49M | — | 517,000 | — |
| Investing Cash Flow | -2.90M | -7.73M | -3.41M | -1.74M | -818,000 | 22.13M | 10.38M | 24.29M | -33.88M | 16.89M | -56.06M | 1.02M | -1.04M |
| Financing Activities | |||||||||||||
| Long-Term Debt Issuance | 20.00M | — | 46.60M | — | 4.95M | 9.87M | 5.65M | — | 1.89M | — | — | — | — |
| Long-Term Debt Payments | -47.36M | -5.00M | — | — | — | — | — | — | — | — | — | — | — |
| Other Financing Charges | — | — | — | — | — | — | — | — | — | — | 57.25M | — | — |
| Financing Cash Flow | -26.76M | -4.59M | 47.11M | 423.82M | 26.22M | 9.87M | 11.78M | — | 68.34M | — | 114.62M | 601,000 | 2.62M |
| Other Cash Details | |||||||||||||
| End Cash Position | 348.89M | 393.98M | 372.57M | 463.00M | 71.46M | 36.82M | 25.24M | 8.35M | 11.89M | 2.18M | 22.10M | 97,000 | 55,000 |
| Income Tax Paid | — | — | — | — | — | — | 35,000 | 12,000 | 1,000 | — | — | — | — |
| Interest Paid | 2.13M | 813,000 | 684,000 | 751,000 | 691,000 | 146,000 | — | — | — | — | — | — | — |
| Free Cash Flow | -21.00M | 24.27M | -138.45M | -44.60M | -7.26M | -22.24M | -711,000 | -3.55M | 8.04M | -28.41M | -7.39M | -1.58M | -2.39M |
Error: Invalid format in Holders JSON file.
Article
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the appointment of Moncef Slaoui, Ph.D., as Chair Designate. Dr. Slaoui has been serving on the Company's Board of Directors since June 2024. “Dr. Moncef Slaoui has a long-proven track record in the pharmaceutic.
Feb 4, 2025
Article
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19
TOKYO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi) announced today that it has received approval for a partial amendment to the manufacturing and marketing approval of “KOSTAIVE® for Intramuscular Injection,” a self-amplifying mRNA vaccine for protection against COVID-19, to include domestic manufacturing sites in Japan. Meiji Seika Pharma and ARCALIS Co., Ltd. (Headquarters: Minami-soma City, Fukushima.
Jan 31, 2025
Article
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate at a fireside chat hosted by Guggenheim Securities SMID Cap Biotech Conference in New York, on Thursday, February 6, 2025, at 10:30 a.m. Eastern Time. Webcast link can be found.
Jan 30, 2025
